ライフサイエンスコーパス: seroreactivity

1 29 (17%) patients had positive Western blot seroreactivity.

2 ns, while <50% of Caucasians with SSc showed seroreactivity.

3 the sera met conventional criteria for HTLV seroreactivity.

4 ral DNA and once (at the later time) for VLP seroreactivity.

5 pect EVD case was negatively associated with seroreactivity [0.23 (95% CI: 0.07, 0.73)].

6 ate antibody to hepatitis E virus (anti-HEV) seroreactivity, 5000 US blood donors were tested for ant

7 pect EVD case was negatively associated with seroreactivity (adjusted odds ratio, 0.23; 95% confidenc

8 ibes changes in blood donor demographics and seroreactivity after testing of blood donations for seve

9 Seroreactivities against at least 2 viral proteins were

10 The detection of high level of seroreactivities against orthoebolaviruses in rural Came

11 We measured immunoglobulin G seroreactivity against 10 polyomaviruses (BKPyV, JCPyV,

12 Seroreactivity against alphaA-, alphaB-, or betaB1-, but

13 Seroreactivity against alphaB and betaB1 was significant

14 rpose of this study was to determine whether seroreactivity against betaB1 or other specific purified

15 Increasing seroreactivity against HHV-6A was detectable before the

16 d M. bovis-infected cattle with little to no seroreactivity against M. kansasii- and M. avium subsp.

17 requently have gastrointestinal symptoms and seroreactivity against secretory granules of Paneth cell

18 Seroreactivity against SOX1 and 2 was consistently highe

19 The significance of anti-HEV seroreactivity among persons without an international tr

20 (NYC) has declined to a record low, syphilis seroreactivity among women jailed in NYC is approximatel

21 e first time an association between a unique seroreactivity and disease.

22 eason, children maintained this differential seroreactivity and recognized additional intracellular P

23 Within-pair ratios of HHV-6A seroreactivity and sNfL were calculated for each case an

24 lts showed a strong association between HIAP seroreactivity and the detection of autoantibodies to do

25 ent measures of sensitization history (e.g., seroreactivity), and allow the simultaneous assessment o

26 structural features, antigenic composition, seroreactivity, and immunogenicity of purified HCV-LPs.

27 dependent increases in average whole-protein seroreactivity, as well as strain-specific responses to

28 Our data also indicate a strong linkage of seroreactivity between apparently distinct serotypes tha

29 Additionally, SV40 seroreactivity confirmed by competitive-inhibition exper

30 eferred to as vaccine-induced seropositivity/seroreactivity, confounds the interpretation of test res

31 assessed associations between anti-EBOV IgG seroreactivity, defined as >=2.5 units/mL and risk facto

32 assessed associations between anti-EBOV IgG seroreactivity, defined as >=2.5 units/mL, and risk fact

33 HIV-1 assay shows 100% agreement with known seroreactivity for a collection of 82 HIV Ab-positive an

34 matous lymphocytic cholangitis, with typical seroreactivity for antimitochondrial antibodies.

35 and cancer patient sera showed anti-NY-LU-12 seroreactivity in 2 of 21 allogeneic lung cancer patient

36 he prevalence of latent yaws with high-titer seroreactivity in a subgroup of children 1 to 15 years o

37 ion protein showed frequent immunoglobulin A seroreactivity in CD (54% of patients), but infrequent s

38 ; P<0.001) with a near-absence of high-titer seroreactivity in children 1 to 5 years of age.

39 G was developed and revealed high-titer MDH seroreactivity in culture-confirmed cases and 5 addition

40 f Leishmania braziliensis, and evaluated the seroreactivity in exposed individuals in search for expo

41 ical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women.

42 In this study we show low seroreactivity in humans against simian- (sAd11, sAd16)

43 vity in CD (54% of patients), but infrequent seroreactivity in patients with ulcerative colitis, othe

44 the accurate determination of PERV-specific seroreactivity in porcine xenograft recipients.

45 Until the basis for HEV seroreactivity in such areas is elucidated, anti-HEV res

46 The high incidence of BA21 seroreactivity in these patients suggests that exposure

47 No new rapid plasmin reagin (RPR) seroreactivity in young children is required for certifi

48 Seroreactivity increased with age, similar to the age-sp

49 l antibiotic therapy; i.e., EMIBA identified seroreactivity indicating a clinical circumstance requir

50 he probability of onward transmission and if seroreactivity is associated with immunity.

51 If the seroreactivity is confirmed by more specific tests, then

52 d have broad PfEMP1 serorecognition and high seroreactivity levels during follow-up, particularly to

53 The seroreactivity levels in swine serum samples and the nuc

54 e (LD), serologic testing is insensitive and seroreactivity may reflect active or past infection.

55 ects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 ma

56 The seroreactivity of p35 was evaluated by immunoblotting ag

57 research to understand the transmissibility, seroreactivity or the potential pathogenicity of Volzhsk

58 The seroreactivity patterns against these five proteins coul

59 patients with active ongoing infection from seroreactivity persisting long after clinically successf

60 ndemic and nonendemic origins demonstrated a seroreactivity rate of approximately 4% that was similar

61 alysis found that only upper-quintile cHsp60 seroreactivity remained a significant predictor of CAD a

62 Based upon the ELISA seroreactivity results, rATP-beta and rGroEL represented

63 hese genes, PFD1140w, and this protein shows seroreactivity similar to that of VAR2CSA domains.

64 ertile women had significantly greater Hsp10 seroreactivity than acutely infected women, indicating a

65 r chitinolytic activity and slightly greater seroreactivity than the bacterially expressed recombinan

66 SV40 seroreactivity therefore may reflect zoonotic exposure.

67 nes, and matrix metalloproteinases; pathogen seroreactivity through peptide display bacteria librarie

68 ARTICLE'S MAIN POINT: Our study found high seroreactivities to Ebola and Sudan orthoebolavirus anti

69 era collected from 14 states were tested for seroreactivity to a cultured isolate of the human granul

70 These data suggest that seroreactivity to a given type reflects mainly type-spec

71 nd immunoblot studies revealed no consistent seroreactivity to a recombinant RD protein by H. pylori-

72 ccination resulted in dramatically increased seroreactivity to all 263 AMA1 whole-protein variants.

73 ity to any type was associated with elevated seroreactivity to all others.

74 In contrast, seroreactivity to any type was associated with elevated

75 nce of endocarditis were included because of seroreactivity to B. vinsonii antigens and uncharacteriz

76 The high prevalence of bacteremia and seroreactivity to Bartonella spp. in gray foxes suggests

77 local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizi

78 tribution of HLA class II Ags along with the seroreactivity to Campylobacter jejuni were investigated

79 Data on seroreactivity to Coccidioides among dogs-which are high

80 Seroreactivity to cutaneous HPV types was highly prevale

81 ed that vaccinated children had increases in seroreactivity to four distinct epitopes that exceeded r

82 The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/

83 y infants expressed the highest level of IgG seroreactivity to intestinal microbiota antigens.

84 ne function, the authors assessed individual seroreactivity to meningioma tumor-associated antigens a

85 mensal microbiota, mostly based on increased seroreactivity to microbial proteins.

86 Sustained seroreactivity to non-CD36-binding PfEMP1s throughout ad

87 Moderate to high frequencies of seroreactivity to PARV4 (63% and 18% in chimpanzees and

88 A single amino acid change was critical to seroreactivity to peptides in a region of AMA1 associate

89 Seroreactivity to PfEMP1 fragments was higher in adults

90 ntrolling for classical CAD risk factors and seroreactivity to the other antigens (cHsp60 OD, P=0.005

91 Seroreactivity to the panel of antigens was significantl

92 through screening for oral HPV infection or seroreactivity to viral antigens.

93 lence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protei

94 Seroreactivity was 0.26% in 387 hospitalized patients ad

95 C. pneumoniae (Cpn) and C. trachomatis (Ctr) seroreactivity was 54% biased towards co-positivity in c

96 HIAP seroreactivity was also strongly associated with the det

97 Seroreactivity was associated with detection of HPV-16 D

98 HIV-1 p24 gag seroreactivity was found in 27 (35%) of 77 patients with

99 Seroreactivity was independently associated with oral co

100 Probability of seroreactivity was not associated with history of NHP bi

101 tectable antibodies to CT antigens, and this seroreactivity was restricted to NY-ESO-1.

102 Seroreactivity was significantly associated with younger

103 HPV-16 seroreactivity was strongly associated with HPV-16 DNA d

104 Seroreactivity was strongly influenced by antigenic vari

105 Additionally, short motifs associated with seroreactivity were extensively shared among hundreds of

106 ylated hemagglutinin enhanced stalk-directed seroreactivity while dampening the head response in immu

107 Finally, seroreactivity with recombinant orf 73 protein exactly p

108 he basis of its specificity, defined as high seroreactivity with sera from individuals infected with

109 hat were born in or before 1915, each showed seroreactivity with the 1918 virus, nearly 90 years afte